兆科眼科(06622.HK)與Somerset達成戰略合作 推進美國業務擴張
兆科眼科-B(06622.HK)宣布,公司與美國領先的大眾化仿製藥生產及供應企業Somerset Therapeutics LLC達成戰略合作,以推進美國業務擴張。
兆科眼科指,今年5月29日,公司與Somerset簽署了供應和分銷協議。根據該協議,兆科眼科將在美國研發藥物,並授予Somerset在該地區申請相關監管核准的獨家權利;待獲得監管批准後,兆科眼科便會生產藥物並供應給Somerset,用於在美國市場的商業化。
兆科眼科董事會主席、執行董事兼行政總裁李小羿表示,美國是醫藥創新領域最關鍵、競爭最激烈的市場之一,兆科眼科早已將美國市場的戰略擴張視為其全球增長願景的優先重點。兆科眼科與Somerset的合作,彰顯了業界對其公司全球領先的研發實力和垂直整合生產能力的認可。這標誌著兆科眼科在拓展美國市場,以及在當地提升品牌聲譽方面,邁出了重要一步。
Somerset主席兼行政總裁Veerappan Subramanian則指,兆科成熟的研發和生產能力,與Somerset致力於為美國醫療體系的患者提供高品質、價格大眾化藥物的承諾相契合。憑藉其在仿製藥市場、知識產權、產品線、監管策略和商業化方面的深厚專業知識,Somerset擁有獨特的優勢,能夠為患者和醫療機構帶來卓有成效的治療方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.